Related Experiment Video

Updated: Mar 20, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Dabrafenib Active in Rare NSCLC Subtype

    Cancer Discovery
    |May 22, 2016
    PubMed

    Insights

    The BRAF inhibitor dabrafenib shows promise for advanced non-small cell lung cancer with the BRAF V600E mutation. Combining dabrafenib with a MEK inhibitor may offer a more effective treatment approach.

    Area of Science:

    • Oncology
    • Pharmacology
    • Genetics

    Background:

    • Advanced non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
    • The BRAF V600E mutation is a key driver in a subset of NSCLC patients, representing a targetable oncogenic alteration.

    Purpose of the Study:

    • To evaluate the efficacy of dabrafenib as a single agent in patients with advanced NSCLC harboring the BRAF V600E mutation.
    • To explore the potential benefit of combining dabrafenib with a MEK inhibitor in this patient population.

    Main Methods:

    • Phase II clinical trial design.
    • Recruitment of patients with advanced non-small cell lung cancer and documented BRAF V600E mutation.
    • Administration of dabrafenib monotherapy and dabrafenib in combination with a MEK inhibitor in separate study arms.

    Main Results:

    • Dabrafenib demonstrated significant single-agent activity in patients with BRAF V600E-mutated advanced NSCLC.
    • Preliminary data suggest that the combination of dabrafenib and a MEK inhibitor may yield superior treatment outcomes compared to dabrafenib alone.

    Conclusions:

    • Dabrafenib is an active agent for BRAF V600E-mutated NSCLC.
    • Combination therapy with dabrafenib and a MEK inhibitor warrants further investigation as a potentially more effective strategy for this specific NSCLC subtype.

    More Related Videos

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

    Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

    Published on: March 1, 2024

    1.9K
    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

    Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

    Published on: March 29, 2024

    1.7K

    Related Concept Videos

    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    5.4K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.0K